Remission from the 5-Fu-Based Chemotherapy to Gemcitabine-Based Chemotherapy-Based on the Pathological Classification of Periampullary Carcinoma: A Case Report and Literature Review

Wei Hu,Zhiqing Duan,Yinuo Zhang,Jing Liu,Jing Bao,Ruqing Gao,Yajie Tang,Tiande Liu,Hu Xiong,Wen Li,Xiaowei Fu,Shousheng Liao,Lu Fang,Bo Liang

DOI: https://doi.org/10.2147/OTT.S372053

IF: 4

2022-08-26

OncoTargets and Therapy

Abstract:Wei Hu, 1, * Zhiqing Duan, 1, * Yinuo Zhang, 1, * Jing Liu, 2, * Jing Bao, 1 Ruqing Gao, 1 Yajie Tang, 1 Tiande Liu, 1 Hu Xiong, 1 Wen Li, 1 Xiaowei Fu, 1 Shousheng Liao, 2 Lu Fang, 1 Bo Liang 1 1 Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China; 2 Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China *These authors contributed equally to this work Correspondence: Bo Liang; Lu Fang, Email ; Background: Periampullary carcinoma, which includes ampullary carcinoma, pancreatic head cancer, distal common bile duct cancer, and duodenal papillary cancer, is a relatively rare malignancy with uncertain therapeutic options. Although several studies have investigated the efficacy of multiple adjuvant chemotherapy regimens for periampullary carcinoma treatment, the optimal regimen remains to be determined. The inherent heterogeneity of the mucosal origin divides periampullary carcinoma into intestinal and pancreaticobiliary types. Therefore, the selection of chemotherapy regimens based on pathological type may have potential therapeutic significance. Case Presentation: A 72-year-old woman with moderately differentiated periampullary adenocarcinoma experienced disease progression after receiving FOLFOX regimen. Subsequently, the sample was subtyped first by H&E evaluation and then by the evaluation of an IHC panel composed of CK20, CDX2, MUC1, MUC2, and MUC5AC. The pathologists concluded that the patient's sample was of the pancreaticobiliary (PB) subtype. The subsequent change to gemcitabine plus S-1 adjuvant therapy achieved remission of liver metastases based on the pathological classification of the cancer. Conclusion: Based on the pathological classification, adjuvant chemotherapy with gemcitabine may be beneficial for patients with PB subtype periampullary carcinoma. 5-Fu-based adjuvant chemotherapy may be beneficial for patients with intestinal subtype periampullary carcinoma. Keywords: periampullary carcinoma, adjuvant chemotherapy, pathological classification, S-1, gemcitabine Periampullary carcinoma, which comprises ampulla of Vater, pancreatic head, distal common bile duct, and duodenal papillary cancers, is a malignant tumor originating 2 cm from the ampulla of Vater. 1,2,38 It constitutes 5% of all gastrointestinal tract malignancies and ranks eighth to ninth in incidence and the fourth to fifth most common cause of mortality in gastrointestinal tract malignancies. 3,4 For patients with localized disease, radical surgical resection is regarded as the mainstay of curative treatment and is feasible in approximately 50% of ampullary cancer cases. 5,6 However, the 5-year survival rate after surgery has been reported to range from 5% to 68%, 7–11 which results from the high risk of recurrence and metastasis. 12,13 Moreover, due to limited adjuvant treatments such as chemoradiotherapy, metastatic and advanced ampullary adenocarcinomas are characterized by poor prognosis, with a 2-year overall survival rate ranging from 5% to 10%. 14 To further improve treatment outcomes, many clinicians now treat patients with periampullary cancer with adjuvant chemotherapy. 15 At present, there are no clear evidence-based guidelines to aid in selecting both the modality and regimen of adjuvant therapy for resected ampullary carcinoma; therefore, the regimens have been inconclusive and are largely based on treatments of other gastrointestinal tract malignancy types, which are mainly fluorouracil-based and gemcitabine-based chemotherapy. However, the optimal choice is still to be determined. 6,16 In addition, many studies have shown distinctly variable treatment outcomes after chemotherapy, which is assumed to be caused by the inherent heterogeneity of the mucosal origin of periampullary cancer. Based on heterogeneous mucosal origin, periampullary cancer can be divided into pancreaticobiliary (PB) subtypes, including pancreatic cancer, distal bile duct cancer, and some ampullary carcinomas, and intestinal (IN) subtypes, including duodenal carcinoma and some ampullary carcinomas; the two subtypes with distinct tissue phenotypes show a significant difference in prognosis and survival rate. 17 As a result, histological subtype is considered an independent prognostic factor affecting overall survival, thus indicating a potential therapeutic direction. 18,19 At present, clinicians tend to treat -Abstract Truncated-

oncology,biotechnology & applied microbiology